These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Iranian HIV/AIDS patients with oropharyngeal candidiasis: identification, prevalence and antifungal susceptibility of Candida species. Khedri S; Santos ALS; Roudbary M; Hadighi R; Falahati M; Farahyar S; Khoshmirsafa M; Kalantari S Lett Appl Microbiol; 2018 Oct; 67(4):392-399. PubMed ID: 30019443 [TBL] [Abstract][Full Text] [Related]
6. Oropharyngeal Candida colonization in human immunodeficiency virus infected patients. Li X; Lei L; Tan D; Jiang L; Zeng X; Dan H; Liao G; Chen Q APMIS; 2013 May; 121(5):375-402. PubMed ID: 23030258 [TBL] [Abstract][Full Text] [Related]
7. Oral Candida isolates among HIV-infected subjects in Nigeria. Nweze EI; Ogbonnaya UL J Microbiol Immunol Infect; 2011 Jun; 44(3):172-7. PubMed ID: 21524610 [TBL] [Abstract][Full Text] [Related]
8. Significance of isolation and drug susceptibility testing of non-Candida albicans species causing oropharyngeal candidiasis in HIV patients. Nadagir SD; Chunchanur SK; Halesh LH; Yasmeen K; Chandrasekhar MR; Patil BS Southeast Asian J Trop Med Public Health; 2008 May; 39(3):492-5. PubMed ID: 18564689 [TBL] [Abstract][Full Text] [Related]
10. In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital. Arikan S; Sancak B; Hascelik G Med Mycol; 2005 Mar; 43(2):171-8. PubMed ID: 15832560 [TBL] [Abstract][Full Text] [Related]
11. Caspofungin in the treatment of oropharyngeal candidiasis. Garbino J; Lew D; Hirschel B; Rohner P Int J Clin Pract; 2003 Mar; 57(2):143-4. PubMed ID: 12661800 [TBL] [Abstract][Full Text] [Related]
12. Post-antifungal effect and adhesion to buccal epithelial cells of oral Candida dubliniensis isolates subsequent to limited exposure to amphotericin B, ketoconazole and fluconazole. Ellepola AN; Chandy R; Khan ZU J Investig Clin Dent; 2015 Aug; 6(3):186-92. PubMed ID: 24850753 [TBL] [Abstract][Full Text] [Related]
13. Species distribution and antifungal susceptibility profile of oral candida isolates from HIV-infected patients in the antiretroviral therapy era. Costa CR; de Lemos JA; Passos XS; de Araújo CR; Cohen AJ; Souza LK; Silva Mdo R Mycopathologia; 2006 Jul; 162(1):45-50. PubMed ID: 16830191 [TBL] [Abstract][Full Text] [Related]
14. Longitudinal study of anti-Candida albicans mucosal immunity against aspartic proteinases in HIV-infected patients. Millon L; Drobacheff C; Piarroux R; Monod M; Reboux G; Laurent R; Meillet D J Acquir Immune Defic Syndr; 2001 Feb; 26(2):137-44. PubMed ID: 11242180 [TBL] [Abstract][Full Text] [Related]
15. Antifungal susceptibility of 95 yeast strains isolated from oral mycoses in HIV-negative and HIV-positive patients. Mareş M; Mareş M; Rusu M Bacteriol Virusol Parazitol Epidemiol; 2008; 53(1):41-2. PubMed ID: 19241996 [TBL] [Abstract][Full Text] [Related]
16. Candida and candidaemia. Susceptibility and epidemiology. Arendrup MC Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246 [TBL] [Abstract][Full Text] [Related]
17. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Villanueva A; Gotuzzo E; Arathoon EG; Noriega LM; Kartsonis NA; Lupinacci RJ; Smietana JM; DiNubile MJ; Sable CA Am J Med; 2002 Sep; 113(4):294-9. PubMed ID: 12361815 [TBL] [Abstract][Full Text] [Related]